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Human leukocyte elastase (HLE) is a broad spectrum serine 
protease derived from neutrophils and macrophages. We de-
veloped an assay to determine HLE activity on the skin sur-
face in patients with inflammatory skin diseases. HLE activ-
ity was absent in the skin of healthy controls. A massive 
increase of HLE activity was found in lesional skin of psoria-
sis (31 times), allergic contact dermatitis (55 times), and 
atopic dermatitis (35 times), but not in uninvolved skin of 
I n contact dermatitis, atopic dermatitis, and psoriasis, distur-bance of epidermal cohesiveness results in the formation of spongiotic vesicles (dermatitis) or focal spongiosis and mi-croabscesses (psoriasis). In both diseases keratinocyte dissocia-tion takes place in the presence of leukocytes. Mechanisms 
leading to the formation of these disease hallmarks are not well 
understood. Whereas lymphocytes and macrophages are found in 
contact dermatitis and atopic dermatitis, polymorphonuclear leuko-
cytes (PMN) and macrophages are the predominating cells within 
psoriatic spongiform pustules and microabscesses (references given 
in [1 D. Whereas loss of intercellular contact of keratinocytes could 
suggest proteolysis of intercellular adhesive proteins (e.g., linked to 
desmosomes), the enzyme(s) involved in these tissue alterations are 
not known. 
Human PMN are known to contain abundant amounts of human 
leukocyte elastase (HLE), a serine protease located within azuro-
philic granules [2) . This enzyme acts as a powerful proinflammatory 
agent, not only by causing degradation of a broad spectrum of ma-
trix components [2-4), but also by its ability to generate chemotac-
tic factors and to cleave antithrombin III (for review see [5)). 
Next to neutrophils as the primary source for HLE, freshly iso-
lated monocytes and U937 monocyte-like cells have been shown to 
secrete HLE [6,7). As a further source, human mast cells have been 
observed to release HLE when specifically stimulated [8). 
In this report we describe an in vivo assay that allows quantitative 
determination of HLE activity on the surface of diseased human 
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Abbreviations: 
EDTA: ethylenediamine tetraacetic acid 
ELISA: enzyme-linked immunosorbent assay 
HEPES: n-[hydroxyethyl] piperazine-N-[2-ethane sulfonic acid] 
HLE: human leukocyte elastase 
MeO-Suc-Ala-Ala-Pro-Val-N A: methoxy-succinyl-alanyl-alanyl-
prolyl-valine-p-nitroanilide 
PMSF: phenylmethylsulfonyl fluoride 
PMN: polymorphonuclear leukocytes 
diseased patients. Therefore, this assay appears to represent a 
useful biochemical marker of epidermal inflammation. T~e 
presence of proteolytically active HLE in diseased epidermis, 
which is known to contain specific inhibitors of this enzym.e, 
suggests a pathophysiologic role of this enzymatic activity In 
psoriasis, contact dermatitis, and atopic dermatitis. ] Invest 
DermatoI99:306-309, 1992 
skin. The results obtained with this assay demonstrate excess HLE 
activities in psoriasis and atopic dermatitis as well as in allergiC 
contact dermatitis. Our observations point toward a protea~e-antli 
protease imbalance that could be related to proteolytic eplderma 
cell dissociation seen in these conditions, similar to the well-esta~­
lished concept of a protease-anti protease imbalance leading to pu -
monary emphysema [9) . 
MATERIALS AND METHODS 
Patients We investigated 34 patients suffering from chronic 
plaque-type psoriasis. Their mean age was 44 years, and the averagd body involvement approximately 15%. None of the patients ?a 
received specific treatment for at least 14 d prior to our investiga-
tions. The control group consisted of 51 healthy volunteers fro~ 
the hospital staff. The contact dermatitis group consisted of 1 
patients with positive patch tests against nickel sulphate (n = 7) or 
formaldehyde (n = 7). The diagnosis of atopic dermatitis in 23 pa-
tients was based on a family history of atopy, typical skin invol~ej 
ment, and the presence of allergic rhinitis or allergic bronchIa 
asthma. 
Sampling Before sampling, the lesions of the patients were 
cleaned with tap water to remove water-soluble components. F.;t 
each patient, two filter papers (3 X 3 em, Schleicher und Schu i 
FRG) were placed on the affected skin surface, soaked with 20~.u 
1 M sodium chloride, and covered with a polyethylene foiL A rr 
10 min, the filter papers were removed and placed in a vIal. °d 
st9rage at-30°C for up to 4 weeks. On average, 90% of the applte 
sodium chloride solution could be recovered. The storage regime 
did not diminish the enzymatic activity. 
Determination of HLE Solubility To determine the optimal 
sodium chloride concentration for elution of HLE activity frod psoriatic skin, the digits of a patient with both hands totally ~overe _ 
by psoriasis were eluted with sodium chloride solutions of Incr~a.s 
ing concentration. Each finger was separately eluted by placing l(t~ 
a vial filled with the sodium chloride solution for 10 mtn d 
fingers, five different concentrations) and subsequently the ~lut~_ 
HLE activity was determined using 100,u1 eluate and 900,u sU _ 
strate solution as described below. The total volume of the recol 
ered sodium chloride solution and the total eluted skin surface (ca f 
culated as the surface of a cylinder using the length and diameter 0 
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each finger) were estimated for standardization of the HLE activity 
per area (em 2) of el uted skin. 
Determination ofLesional HLE Activity For the determina-
tion of HLE activity, 1.8 ml of a specific substrate solution was 
added to each vial containing the filters . The substrate was freshly 
prepared by dilution of a 0.1 M stock solution of methoxy-succinyl-
alanyl-alanyl-prolyl-valine-p-nitroanilide (MeO-Suc-Ala-Ala-Pro-
Val-NA, Sigma) in Me2SO to aO.s mMsolution inO.l M (HEPES) 
0.5 M NaCl, pH 7.5. The substrate solution showed no detectable 
spontaneous hydrolysis within 48 h. The release of p-nitroaniline 
:vas determined after 10, 100, or 1000 min depending on the activ-
Ity that could be observed by the development of a visible yellow 
color. Released p-nitroaniline was spectrophotometrically quanti-
tat~d at 405 nm in comparison with a substrate control. The molar 
extmction coefficient of p-nitroaniline was found to be 10,690 1 X 
lUol- 1 under these assay conditions. Below an absorbance of2.0 the 
reaction was linear up to 48 h, as proved by the use of purified HLE 
~El astin Products Corporation, Pacific, Mo, USA). Enzymatic activ-
Ity was standardized to mUjcm2 eluted skin, where 1 U releases 
1 ,umol p-nitroaniline per min. 
Inhibitor Profiles To establish the inhibitor profiles of HLE-
like activities derived from psoriatic lesions, we produced skin 
eluates from the whole body except the head by wrapping psoriatic 
patients in a watertight polyethylene foil filled with 2125% sodium 
c~loride solution. The patients were then placed in a bathtub filled 
with tap water to achieve the counter-pressure to moisten the 
whole-body surface [10]. After a 1 O-min bath the eluates were recov-
ered and concentrated by Amicon YMs ultrafiltration. The concen-
trated eluates were centrifuged for 30 min at 6000 X g, filtered 
(S ,urn), and then diafiltered against 0.1 M HEPES, 0.5 M NaCl, 
pI-! 7.5. Aliquots (100 ,ul) and purified HLE of comparable activity 
(Elastin Products Corporation, Pacific, Mo, USA) were incubated 
with 100,ul of each inhibitor solution for 30 min at 21·C before 
adding 800,u1 substrate solution (0.5 mM MeO-Suc-Ala-Ala-Pro-
Val-NA in 0.1 M HEPES, 0.5 M NaCl, 10% Me2So, pH 7.5). All 
Inhibitors were purchased from Sigma, except recombinant eglin C 
(kindly provided by Dr. Schnebli, Basel, Switzerland) and ~lafin, 
wluch was prepared as described previously [11] . After 30 m111 111-
cubation, released p-nitroaniline was determined spectrophotomet-
ncally at 405 nm versus enzyme-free controls. Inhibition was ex-
pressed as percent of inhibitor-free controls. 
Statistical Analysis Comparisons between patients and healthy 
Controls were made by evaluating the median and the 95% confi-
dence interval of the median, especially because in case of measure-
ments in psoriasis a bell-shaped distribution curve could not be O~tained. Statistical significance of differences was determined by 
t e use of the X2-test for medians. Significance was assumed for 
p « 0.05. 
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Figure 1. Separate elution of 2 X 5 fingers affected by psoriasis with 0-
1 M NaCI. Spectrophotometric determination of eluted HLE activity 
(MeO-Suc-Ala-Ala-Pro-Val-NA hydrolysis). 
this table, well-known inhibitors of HLE (e.g., recombinant eglin 
C, ai-proteinase inhibitor, soybean trypsin inhibitor, PMSF) 
blocked the enzymatic activity of the skin eluate as well as HLE in a 
nearly identical manner. Metalloprotease inhibitors such as ethy-
lenediamine tetraacetic acid (EDTA) or 1,10 o-phenanthroline 
were without inhibitory activity for both enzyme preparations. 
Aprotinin showed only slight inhibition of the enzymatic activity 
from psoriatic skin and native HLE activity. 
Because HLE represents a highly stable protease and the peptide 
substrate MeO-Suc-Ala-Ala-Pro-Val-NAshows no spontaneous hy-
drolysis within 48 h, we were able to demonstrate a linear enzy-
matic reaction for up to 48 h under optimal assay conditions for 
purified HLE (Fig 2) and psoriatic eluates (data not shown). Using 
this assay for ex vivo determination of HLE activity on the skin 
surface the lower detection limit was found to be 0.3 m U j cm2 skin 
(data not shown). 
Results from quadruple HLE activity determinations in eight 
patients with psoriasis vulgaris are shown in Fig 3. All patients 
examined revealed increased HLE activities. Interestingly, nearly 
half of the patients showed only moderately elevated elastase levels 
(approximately 1 mU jcm2 skin, Fig 3), whereas the other half (pa-
tients E-H) averaged approximately 30 mU/cm3 skin. 
Subsequently, HLE activity was determined in 34 unselected pso-
riasis patients (Fig 4) and showed a 31 times increase compared with 
healthy volunteers. In uninvolved psoriatic skin, no increased HLE 
activity could be observed. Furthermore, as with psoriatic patients 
Table I. Inhibition of Elastase Activity in Eluates of Psoriatic 
Skin Compared with Purified HLEo 
RESULTS Inhibition of HLE 
~ulUan leukocyte elastase is known to be nearly insolubleln water. 
he enzyme, however, can be solubilized with concentrated salt 
Solutions [12,13]. To establish the optimal salt concentration neces-
s~ry for elution of HLE from human skin, test areas symmetrically 
a ected by psoriasis were chosen. Data shown in Fig 1 were ob-
tallled from a patient with all digits totally affected by psoriasis. As 
can be seen, elution of HLE activity from the psoriatic skin surface 
h~creases almost linearly from 0.1 to 1.0 M NaCl, whereas with 
llgher concentrations (4.6 M NaCl) no further activity can be e Uted. 
To ascertain substrate specificity, we determined the inhibition 
Phofile of psoriatic skin enzyme activities. This was compared with 
t e lllhibition profile of native HLE (Table I). As can be seen from 
Activity 
Inhibitors Eluates HLE 
1,10 phenanthroline 7 0 
EDTA 1 0 
SBTI 85 82 
Rec. eglin C 100 100 
PMSF 74 95 
Aprotinin 36 19 
aI-proteinase inhibitoch 100 99 
• Final concentrations of34 ng HLE/ml and psoriatic skin eluates (activity equivalent 
to 8.8 ng HLE/ml) were pre-incubated with protease inhibitors, 100 Jig/ ml for 30 min 
at 21°C before adding the substrate (Meo-Suc-Ala-Ala-Pro-Val-NA). 
! 1251lg/ml protease inhibitors. 
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Figure 2. Linearity of the determination of lesional elastase activity. Puri· 
fied HLE 2.5 ng (bottom curve), 5 ng (center curve), and 10 ng (top curve) in 
100 ILl 1 M NaCI was incubated with 900 ILl substrate solution containing 
0.5 mM MeO-Suc-Ala-Ala-Pro-Val· NA, 0.1 M HEPES, 0.5 M NaCI, and 
0.02% (v/v) Me2S0, pH 7.5 at 21·C for up to 48 h. 
the affected skin in atopic patients or in acute contact dermatitis 
showed significantly increased elastase activities (Fig 5). The aver-
age enzyme activities recovered in these three skin conditions were 
close to 10 mU/cm2 skin. 
DISCUSSION 
Human leukocyte elastase is contained within the azurophilic gran-
ules of PMN, which are released from activated cells leading to 
biologically active extracellular HLE [2]. This proteolytic serine 
proteinase is able to degrade a number of extracellular matrix pro-
teins. Besides elastin, HLE cleaves collagen type III [3] and type IV 
[4] as well as proteoglycans (for review see [5]). Recently it could be 
shown that HLE is also able to degrade human keratins [14]. 
In inflammatory skin diseases, such as psoriasis, atopic dermatitis 
and allergic contact dermatitis dissociation of keratinocytes takes 
place, leading to the hallmarks of these diseases such as spongiosis 
(dermatitis) and spongiform pustules (psoriasis) as well as scaling. 
The loss of intercellular contacts suggests an involvement of pro-
teases. Therefore, we became interested in the question whether 
HLE, which seems to be a very good candidate for extracellular 
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Figure 3. Variation ofHLE activity on the surface oHour separate lesions in 
eight patients with psoriasis . 
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Figure 4. Surface elastase activity of psoriatic lesions. Elution of 9 cm2 
lesion with 1 M NaCl for 10 min and subsequent determination of HLE 
activity (MeO-Suc-Ala-Ala-Pro-Val-NA hydrolysis) . Results are expressed 
as the median and 95% confidence interval of duplicate determinations. 
matrix proteolysis, is present on the lesional skin surface in enzyma-
tically active form. 
We have developed an assay for the dete.rmination of HLE actiV-
ity o~ the surface of human skin using a newly developed salt ex-
traction method and spectrophotometric quantification of the enzy-
matic activity. This assay represents a sensitive, specific and simple 
procedure for the determination of HLE activity on the surface of 
human skin. The tetrapeptide substrate MeO-Suc-Ala-Ala-pro-
Val-NA is known to react specifically with HLE and not with oth~r 
neutrophil-derived serine proteases [15,16]. The identity of skIn 
elastase activity with HLE has been further substantiated by a com-
parable inhibition profile (Table I) and by a HLE_enzyme-linke.d 
immunosorbent assay (ELISA) using a polyclonal anti-elastase anti-
body (data not shown) . The unusual stability of both substrate and 
HLE made it possible to follow a linear enzymatic reaction for up to 
48 h with purified HLE (Fig 2) as well as with patients' samples. 
This resulted in a high sensitivity of this spectrophotometric assay, 
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Figure 5. Surface elastase activity of affected skin of patients with cont;ct 
dermatitis and atopic dermatitis . Elution of9 cm2lesion with 1 M NaCl r 
10 mill and subsequent determination ofHLE activity (MeO_Suc-Ala-A a 
Pro-Val-NA hydrolysis) . Results are expressed as the median and 95% con-
fidence interval of duplicate determinations. 
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which is comparable with the sensitivity of the fluorometric HLE 
determination reported by Lammers et al [12]. 
In a clinical study, we revealed highly increased HLE activity on 
the affected skin surface of patients with psoriasis, contact dermati-
tiS, and atopic dermititis in contrast to healthy controls as well as the 
unaffected skin of these patients. 
. In psoriasis, HLE activity was recovered from lesional skin surface 
111 a 31 times excess as compared with healthy control skin (Fig 4). 
The highest activity obtained from psoriatic lesions was approxi-
mately 10,000 times the normal value. HLE activity determinations 
of separate lesions from the same patient varied within one order of 
magnitude (Fig 3), which seems to reflect a variable distribution 
~attern of inflammatory foci within psoriatic lesions. Earlier inves-
tigations conducted in our laboratory showed that spot-by-spot elu-
tlO~ of psoriatic plaques (approximately 40 mm2) resulted in highly 
vanable enzyme activities within one plaque [10]. 
In patients suffering from allergic contact dermatitis and atopic 
dermatitis, HLE-like ac.tivities on the surface of affected skin were 
55 and 35 times elevated as compared with healthy skin (Fig 5). 
Because neutrophils do not playa major role in these conditions, 
other sources of increased HLE-like activities need to be considered. 
In a recent report Campbell et al [7] have demonstrated rapid release 
of HLE from human monocytes. However, the contents of elastase 
present in these cells amounted to 6.2% of the enzyme content 
present in a comparable number of PMN. Although great numbers 
of macrophages are seen in skin of allergic contact dermatitis and 
atopic dermatitis, the comparatively small amount of HLE con-
ta111ed in these cells as compared with PMN makes it difficult to 
e.xplain the high HLE-like activity detected in these skin condi-
tions. Therefore, other sources need to be considered. It is possible 
that HLE derived from mast cells [8] may contribute to the enzy-
matic activity on the skin surface. However, the presence ofHLE in 
mast cells is not unanimously accepted [17]. 
In Contrast to affected skin, no significant amounts of elastase 
Were detected in uninvolved psoriatic skin or healthy skin from 
COntrol individuals (Fig 4). As in psoriasis, non-affected sites in 
patients suffering from contact dermatitis and atopic dermatitis re-
vealed no increase in elastase activities (data not shown). These 
findings suggest that in lesional skin the proteolytic activity of 
elastase escaped the control of known tissue inhibitors ofHLE, e.g., 
ex[ I-proteinase inhibitor [18], antileukoprotease [18,19], or elafin 
19-21]. 
In consequence, it appears likely that free enzyme activities de-
tected in lesional skin could be related to epidermal damage (e.g., 
Spongiosis, formation of vesicles and microabscesses) known to be 
present in the conditions studied. Studies by Dubertret et al [22] 
revealed that, in contrast to healthy individuals, psoriatic biopsies 
Without fixation undergo marked epidermal proteolytic degrada-
tion with time. Determination of the inhibitor profile showed that 
these proteolytic changes were caused by a serine protease similar to 
HLE. On the other hand, by incubating freshly prepared human 
sk111 strips with purified HLE, Briggaman et al [23] observed that 
thiS enzyme is able to degrade the basement membranes only. These 
results, although they may appear contradictory, do not exclude the 
possibility that under such experimental conditions intracellular 
Inhibitors of HLE (e.g., elafin) may be released into the epidermal 
extracellular space, thereby preventing epidermal proteolysis. 
In addition, the HLE assay described here uses proteolytic activity 
ro ~uantify epidermal inflammation irrespective of its pathophysio-
oglc nature. The assay may be helpful to quantitate epidermal in-
flammation with the further advantage that it can easily be applied 
Without harming the patient. 
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